What J&J Winning One Talc Cancer Trial Means for Your Claim
You saw the headline — Johnson & Johnson beat a lawsuit claiming its talcum powder caused three women’s cancer. Maybe you have ovarian cancer yourself and used baby powder for years. Maybe your mother or sister did, and she is gone. Maybe you are reading at 2 a.m. with a pathology report on the kitchen table, wondering whether the word “mesothelioma” in it connects to a bottle of Shower to Shower that sat on the bathroom shelf for two decades.
Here is the first thing you need to hear, and it is the truest thing on this page: one jury verdict for the defense does not close the courtroom door. More than 68,000 talc cases remain consolidated in one federal court in New Jersey. Johnson & Johnson tried to wall those cases off inside a bankruptcy it engineered on purpose — three separate times — and a federal judge threw it out every single time. The cases are back in the civil justice system, and they are being tried one at a time. Some plaintiffs win. Some do not. That is how mass tort litigation works, and it is why the specific facts of your exposure, your diagnosis, and your history — not the headline about someone else’s trial — decide whether you have a case.
We are Attorney911 — The Manginello Law Firm. Ralph Manginello has spent 27-plus years in courtrooms, including federal court, building product-liability and toxic-exposure cases against corporations that knew more than they told. Lupe Peña spent years inside a national insurance-defense firm before he came to our side of the table — he sat in the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like you. We handle toxic tort claims and wrongful death cases with the seriousness they deserve, and we do it in English or in Spanish. The consultation is free, and we do not get paid unless we win your case.
What a Defense Verdict Actually Means in a Mass Tort
When a jury returns a defense verdict in a talc case, the headline reads as a clean win for the company. The reality is more layered. A defense verdict in one trial means that specific jury, hearing that specific evidence, from those specific plaintiffs, in that specific courtroom, was not persuaded that talc caused those particular women’s cancer. It does not mean the science is settled. It does not mean the 68,000 other cases are dismissed. It does not mean Johnson & Johnson is cleared.
Here is how mass tort litigation actually works. When tens of thousands of people sue the same company over the same product, the federal courts consolidate the pretrial work — document discovery, expert challenges, depositions of corporate executives — into a single proceeding called a Multidistrict Litigation, or MDL. That MDL is numbered 2738 and sits before Judge Michael A. Shipp in the U.S. District Court for the District of New Jersey. As of mid-2026, it held more than 68,000 pending actions. Inside that MDL, a small number of cases are selected as “bellwether” trials — test cases designed to show both sides how juries respond to the evidence. The results are mixed by design. Some plaintiffs win large verdicts. Some lose. Each outcome teaches the lawyers something about what works and what does not, and each outcome pushes the litigation closer to either global settlement or individual resolution.
The defense verdict you read about is one data point in a litigation that has produced verdicts going both directions. In 2018, a Missouri jury awarded 22 women $4.69 billion in a talc-ovarian-cancer case against Johnson & Johnson — the largest talc verdict on record. On appeal, the Missouri Court of Appeals reduced that to approximately $2.12 billion. The Missouri Supreme Court declined to review it. In June 2021, the United States Supreme Court denied certiorari — meaning the reduced award stood. That is not a press release. That is a number the highest court in the country let stand. And on the other side of the ledger, J&J has won individual trials too. That is the nature of bellwether litigation. The reader who sees one headline and concludes the door is closed has misunderstood the system — and the company is counting on exactly that misunderstanding.
The Talc Litigation: 68,000 Cases and Three Failed Bankruptcies
The most important structural fact in the talc litigation is not any single verdict. It is that Johnson & Johnson tried to use bankruptcy to cap its liability — and failed three times.
Here is what happened. In 2021, J&J executed a maneuver called a “Texas two-step” divisional merger. It split its consumer business, transferring all talc-related liability into a newly created entity called LTL Management LLC. That entity immediately filed for Chapter 11 bankruptcy. The strategy was designed not because J&J was broke — it is one of the most profitable companies on earth — but because bankruptcy court allows a judge to impose a global settlement that caps liability across all remaining claims, binding even people who never agreed to settle. A bankruptcy trust would pay pennies on the dollar, and J&J would walk away with its liability permanently capped.
The bankruptcy court saw through it. The first LTL filing was dismissed in 2023 after the court found the company was not in genuine financial distress. LTL filed again. That too was dismissed. Then J&J created a successor entity called Red River Talc LLC and filed a prepackaged Chapter 11 — the third attempt. On March 31, 2025, U.S. Bankruptcy Judge Christopher Lopez of the Southern District of Texas denied confirmation and dismissed the case, citing vote-solicitation irregularities and impermissible nonconsensual third-party releases. Three filings. Three dismissals. The cases are now back in the tort system, being tried individually.
What this means for you: the company’s primary strategy for capping liability has failed. The cases are proceeding. The courtroom door is open. And J&J now faces the prospect of trying thousands of cases one at a time — which is exactly the pressure that drives settlement.
The Science: Talc, Asbestos, and Cancer — Two Separate Theories
Talc litigation rests on two distinct scientific theories, and understanding which one applies to your situation is the first step in evaluating your case.
The Ovarian Cancer Theory
The first theory involves ovarian cancer. The causal theory is that talc particles applied to the perineal area — the genital region — can travel through the vagina, cervix, uterus, and fallopian tubes into the ovaries, where they cause chronic inflammation that can lead to malignant transformation. Talc particles have been identified in ovarian tissue in pathology studies. Multiple epidemiological studies have examined whether women who used talc in the genital area had higher rates of ovarian cancer, and some have found a modestly elevated risk while others have not. This is a genuinely contested area of science — and the defense exploits every gap in it.
What the defense argues: that the association is weak, that the studies are inconsistent, that ovarian cancer has many causes (BRCA mutations, family history, age, hormone use, endometriosis), and that any individual’s cancer cannot be attributed to talc use with any confidence. They bring epidemiologists who testify that the relative risk is too small to establish specific causation.
What the plaintiff argues: that the body of evidence, taken together, supports an association; that talc particles have been physically found in ovarian tissue; that J&J’s own internal documents show it was aware of concerns about talc and ovarian cancer for decades; and that the company chose not to warn consumers despite having the information.
The Mesothelioma Theory
The second theory is different and in some ways stronger. It involves mesothelioma — a cancer of the lining of the lungs or abdomen that is essentially specific to asbestos exposure. The causal theory here is that some talc deposits are naturally contaminated with asbestos, specifically tremolite or anthophyllite asbestos, because talc and asbestos form under similar geological conditions. If asbestos-contaminated talc was mined, processed, and sold as baby powder or body powder, consumers would have inhaled asbestos fibers with each use.
The science on this is less contested. Asbestos is classified by the International Agency for Research on Cancer as a Group 1 known human carcinogen — the highest certainty category. Mesothelioma is so asbestos-specific that the disease itself is near-conclusive evidence of asbestos exposure. The question in these cases is not whether asbestos causes mesothelioma — it does — but whether J&J’s specific talc products contained asbestos, and whether the plaintiff used those products.
This is where J&J’s internal documents become the spine of the case. Reporting and litigation discovery have revealed that J&J’s own testing, going back to the 1970s and continuing through the decades, detected asbestos in its talc on multiple occasions. The company’s internal communications discussed how to manage the public-relations and regulatory implications. In 2018, a major news investigation published internal J&J documents showing the company knew for decades that its raw talc sometimes tested positive for asbestos. In 2019, Johnson & Johnson voluntarily recalled a lot of its Baby Powder after the FDA reported finding trace amounts of asbestos in a sample — though J&J disputed the finding and stated its product was safe. The company stopped selling talc-based Baby Powder in the United States and Canada in 2020, and has since transitioned to cornstarch-based products globally.
The defense responds to the asbestos theory by arguing that its talc was purified, that any asbestos detected was at trace levels below any meaningful risk threshold, and that the plaintiff cannot prove they used a contaminated lot. The plaintiff counters with the pattern of internal testing results, the geological reality that talc and asbestos co-occur, and the fact that mesothelioma in a person with significant talc exposure and no other known asbestos source is itself powerful circumstantial evidence.
Who Is Johnson & Johnson — The Corporate Structure
Johnson & Johnson is not a single entity you can point at and sue. It is a layered corporate family, and understanding that structure matters because it determines who you name in the caption, whose insurance tower applies, and who actually pays.
The parent company is Johnson & Johnson — a New Jersey corporation, one of the largest healthcare companies in the world, with revenues exceeding $80 billion annually. It is what lawyers call a “balance-sheet defendant” — it does not need an insurance policy to pay a verdict. The company itself is the deep pocket.
The historical seller of talc products was Johnson & Johnson Consumer Inc. (JJCI), a subsidiary. The products — Johnson’s Baby Powder, Shower to Shower, and others — carried the JJCI label. When J&J spun off its consumer health business in 2023, the new public company was named Kenvue Inc. Kenvue now owns brands like Band-Aid, Tylenol, and Listerine. J&J retained indemnity obligations related to talc liability, meaning that even though Kenvue now holds the consumer brands, J&J is the entity that must answer for the talc lawsuits.
The bankruptcy shell entities — LTL Management LLC and Red River Talc LLC — were created specifically to hold talc liability and file for bankruptcy. Both are now defunct as litigation vehicles after the three dismissals. The cases are proceeding against J&J and JJCI directly.
What this means practically: when a talc case is filed, the defendants are Johnson & Johnson and its consumer subsidiary. The company is self-insured at massive scale. There is no insurance policy ceiling to worry about — the corporation’s own balance sheet is the coverage. The question is never “is there money to recover.” There is. The question is whether the evidence connects your specific cancer to their specific product.
The Evidence That Decides Talc Cases
Talc cases are built from four categories of evidence, and the strength of each category is what separates a winning case from a losing one. The defense verdict you read about likely turned on one or more of these categories being weak for those particular plaintiffs.
Product Usage History
The first and most foundational piece of evidence is your personal history of talc use. What product did you use — Johnson’s Baby Powder, Shower to Shower, a store brand? How often — daily after every shower, occasionally, only for a specific period? How did you use it — genital application, body dusting, on sanitary napkins? How many years — two, ten, thirty?
This is proven through your own testimony, family member corroboration, purchase receipts (if they exist), and sometimes through patterns of consumption. The defense attacks this evidence by arguing the usage was too infrequent, too brief, or too distant in time to have caused the cancer. In cases where the plaintiff cannot clearly identify the specific product or the frequency of use, this is where the defense verdict often originates.
Internal Corporate Documents
The second category — and the one that has driven the largest verdicts — is J&J’s own internal documents. These include decades of testing records showing asbestos detections in talc, internal communications about managing the regulatory and public-relations implications, and documents showing awareness of the ovarian cancer concerns. These documents were produced through litigation discovery and have been reported in major news investigations. They are the evidence that transforms a case from “a product might have caused my cancer” to “the company knew its product was dangerous and sold it anyway.”
The challenge: these documents exist in the MDL’s shared evidence repository, but using them effectively in an individual case requires the kind of expert analysis that connects the corporate knowledge to your specific exposure timeline.
Medical and Pathological Evidence
The third category is your medical record. What type of cancer do you have — ovarian, mesothelioma, another type? When were you diagnosed? What does your pathology show? For mesothelioma cases, pathology tissue blocks can sometimes be analyzed for the presence of talc and asbestos fibers, providing physical evidence that the carcinogen was in your body. For ovarian cancer cases, talc particles have been identified in ovarian tissue in some studies, and tissue analysis can be performed.
This is also where the defense attacks hardest. They argue your cancer has other causes — genetic predisposition for ovarian cancer, other asbestos exposure for mesothelioma, or idiopathic causes that cannot be traced to any specific exposure. The plaintiff’s medical experts must connect the exposure to the disease through specific causal reasoning, not just general association.
Regulatory and Scientific Evidence
The fourth category includes FDA testing records, regulatory actions, epidemiological studies, and the broader scientific literature. The FDA has conducted testing of cosmetic talc products for asbestos contamination. J&J’s 2019 recall — voluntary, though the company disputed the FDA’s finding — is part of this record. The IARC classification of asbestos as a Group 1 carcinogen is settled science. The epidemiological literature on talc and ovarian cancer is part of the evidentiary landscape, though it is more contested.
How Fast Evidence Dies
The evidence in a talc case faces two clocks. The first is the statute of limitations, which we discuss below. The second is the practical preservation of evidence. Talc product containers in your home can be lost, discarded, or degrade over time. Medical pathology blocks are retained by hospitals for a set number of years — typically 10 years or longer, but not indefinitely, and once a hospital purges them, the physical evidence of asbestos or talc fibers in your tissue is gone. Family members who can corroborate your usage history age and pass away. The preservation letter that demands a hospital hold your pathology blocks, that asks family members to provide written statements while their memories are sharp, and that documents your product usage history before it fades — that letter goes out the day you call us.
The Medicine: Ovarian Cancer and Mesothelioma
Ovarian Cancer
Ovarian cancer is a malignancy that begins in the ovaries or the fallopian tubes. It is the fifth-leading cause of cancer death among women in the United States. The lifetime risk of developing ovarian cancer is approximately 1 in 78 — roughly 1.3 percent. The disease is notoriously difficult to detect early because its symptoms — bloating, pelvic pain, urinary urgency, feeling full quickly — are vague and easily attributed to other conditions. By the time most ovarian cancers are diagnosed, they have spread beyond the ovaries.
The causal link between talc use in the genital area and ovarian cancer is the most contested scientific issue in the litigation. Some epidemiological studies have found a small but statistically significant increase in risk among women who used talc in the perineal area. Others have not. The International Agency for Research on Cancer has classified perineal use of talc-based body powder as “possibly carcinogenic to humans” (Group 2B) — a category that indicates limited evidence but enough concern to warrant caution. The defense leans heavily on the word “possibly” and the weaker Group 2B classification, while plaintiffs point to the totality of the evidence and the physical presence of talc in ovarian tissue.
What the family observes: a woman diagnosed with ovarian cancer faces surgery (often a total hysterectomy with bilateral salpingo-oophorectomy), chemotherapy, and a five-year survival rate that depends heavily on the stage at diagnosis. Stage III and IV ovarian cancer — the most common stages at diagnosis — carry five-year survival rates of approximately 35-40 percent. The treatment is brutal. The recovery is uncertain. And the question of whether a product she used every day for decades contributed to the disease is one she may never answer with certainty — but the law does not require certainty. It requires a preponderance of the evidence. More likely than not.
Mesothelioma
Mesothelioma is a cancer of the mesothelium — the thin lining that covers the lungs, the abdominal organs, and occasionally other surfaces. It is essentially specific to asbestos exposure. The latency period — the time between first exposure and diagnosis — is typically 20 to 50 years, most commonly 30 to 40 years. A person exposed to asbestos in their twenties through talc use may not be diagnosed until their sixties or seventies.
The symptoms of pleural mesothelioma (the most common form) include shortness of breath, chest pain, and fluid accumulation around the lungs. Diagnosis typically involves imaging (CT, PET), biopsy, and immunohistochemical staining to distinguish mesothelioma from adenocarcinoma. Median survival from diagnosis is approximately 12 to 21 months, though newer treatments including immunotherapy have extended survival in some patients. The disease is almost always fatal.
What the family observes: mesothelioma moves fast. A person who was healthy six months ago is now in a wheelchair, on oxygen, facing chemotherapy that may buy months but rarely years. The cruelty of the disease is compounded by its latency — the exposure that caused it happened so long ago that the patient may have half-forgotten it. Tying the disease back to a bottle of body powder used decades earlier requires the kind of exposure reconstruction that only an experienced attorney with the right experts can build.
What Your Talc Case Is Worth
No honest lawyer can tell you exactly what your case is worth without reviewing your medical records, your exposure history, and the specific facts of your situation. But we can tell you what drives value in these cases and what the landscape looks like.
The largest verified talc verdict is the Ingham case — 22 plaintiffs in Missouri who alleged ovarian cancer from talc use. The jury awarded $4.69 billion in July 2018. On appeal, the Missouri Court of Appeals reduced this to approximately $2.12 billion. The U.S. Supreme Court declined to hear the case in June 2021, meaning the reduced award stands as final. That figure — approximately $2.12 billion for 22 plaintiffs — translates to roughly $95 million per plaintiff, though the actual per-plaintiff amounts varied based on individual damages.
Individual talc verdicts have ranged widely — from defense verdicts (zero recovery) to awards in the millions and tens of millions for individual plaintiffs. Factors that drive value include:
- The type of cancer: Mesothelioma cases, with their clear asbestos link, tend to carry higher value than ovarian cancer cases, where the science is more contested.
- The strength of exposure evidence: A plaintiff who can document 30 years of daily genital talc use has a stronger case than one who used it occasionally for a few years.
- The jurisdiction: Some jurisdictions are more plaintiff-friendly than others. The venue where your case is filed matters.
- The quality of medical evidence: Pathology that shows talc or asbestos fibers in tissue is powerful. A clear diagnosis with no confounding causes is stronger than one with alternative explanations.
- The age and economic loss of the plaintiff: A younger plaintiff with more lost earning capacity and more years of lost life carries higher economic damages.
- Punitive damage exposure: If the evidence shows J&J knew about the danger and concealed it, punitive damages — designed to punish — can multiply the award substantially. The Ingham verdict included a significant punitive component.
The costs of these cancers are enormous. Ovarian cancer treatment — surgery, chemotherapy, follow-up care — can run into the hundreds of thousands of dollars. Mesothelioma treatment, including surgery, chemotherapy, immunotherapy, and palliative care, can exceed a million dollars. Lost wages, lost earning capacity, and the cost of family caregiving add to the economic loss. And then there are the human losses — the pain, the fear, the life that will not be lived the same way again — which the law calls non-economic damages and which are recoverable in every jurisdiction, though some states cap them.
What a defense verdict in one trial tells you about value: it tells you that weak cases — those with thin exposure evidence, contested causation, or unfavorable jurisdictions — can lose. It does not tell you that strong cases are worthless. It tells you to get the facts right, to preserve the evidence, and to have a lawyer who knows the difference.
Past results depend on the facts of each case and do not guarantee future outcomes.
The Defense Playbook: How J&J Fights These Cases
Johnson & Johnson has spent years refining its defense strategy, and the playbook is consistent across trials. Here are the moves you should expect — and how each one is countered.
Play 1: Attack Causation
The defense’s first and most powerful move is to attack the causal link. For ovarian cancer, they bring epidemiologists who testify that the studies showing a talc-ovarian cancer link are flawed, that the relative risk is too small to establish specific causation, and that your cancer had other causes — genetics, hormones, age, bad luck. For mesothelioma, they argue that your asbestos exposure came from somewhere else — a workplace, a building, a family member’s work clothes — not from baby powder.
The counter: The plaintiff’s experts present the totality of the evidence — the epidemiological studies, the pathology findings, the exposure reconstruction, and the internal documents showing J&J knew its talc contained asbestos. For mesothelioma, the absence of any other known asbestos exposure is itself powerful evidence. For ovarian cancer, the plaintiff’s expert must walk the jury through the biological mechanism — talc traveling to the ovaries, causing inflammation, leading to malignant transformation — and connect it to the plaintiff’s specific usage history.
Play 2: Attack Exposure Evidence
The defense argues that the plaintiff cannot prove they used J&J’s talc specifically, that they used it frequently enough, or that they used it in the manner alleged (genital application for ovarian cancer cases). They point to the absence of receipts, the absence of product containers, the reliance on decades-old memory.
The counter: Corroborating testimony from family members, photographs showing the product in the home, consistent usage patterns, and the fact that Johnson’s Baby Powder was the dominant brand for decades — making it the most likely product a woman used. The preservation of family testimony and any physical evidence (old containers, photographs) is critical and time-sensitive.
Play 3: Attack the Asbestos Theory
In mesothelioma cases, J&J argues its talc was asbestos-free. They present their own testing protocols, their purification processes, and their experts who testify that any asbestos detected was at trace levels below any meaningful risk. They point to the fact that the FDA did not require warnings and that the company met all regulatory standards.
The counter: The internal documents. J&J’s own testing — not the plaintiff’s experts, but the company’s own scientists — detected asbestos in its talc on multiple occasions over decades. The company’s internal communications discussed how to present the findings to regulators and the public. The 2019 FDA finding and voluntary recall, while disputed by J&J, are part of the record. And the geological reality — talc and asbestos form under the same conditions, making contamination a known risk — is settled science.
Play 4: Regulatory Compliance Defense
J&J argues that it complied with all applicable FDA regulations, that the FDA did not require warnings on talc products, and that the FDA did not ban talc in cosmetics. They frame compliance as proof of safety.
The counter: FDA regulation of cosmetics is notably weak. Unlike drugs and medical devices, cosmetics are not approved by the FDA before they go to market. The FDA does not test cosmetic ingredients for safety before they are sold. The absence of a warning requirement is not a finding of safety — it is a gap in the regulatory system. A company that knows its product is dangerous and chooses not to warn consumers, simply because the government did not force it to, has still failed in its duty of care. Compliance with a weak regulatory floor is not a defense to a failure-to-warn claim.
Play 5: The Bankruptcy Strategy (Now Failed)
J&J’s most aggressive move — the Texas two-step bankruptcy — was designed to cap all liability at once. By creating a shell entity, transferring liability to it, and filing for bankruptcy, J&J hoped to force a global settlement that would bind every claimant, including those who never agreed. Three times the bankruptcy courts refused. The strategy is dead. But the company may try again with a different structure, and the reader should know that any news of a new J&J bankruptcy filing related to talc is a signal to act quickly, because bankruptcy proceedings can freeze individual litigation.
The Proof Story: How a Talc Case Is Actually Built
Building a talc case is a chronological process that begins the day you call and continues through resolution. Here is what it looks like from the inside.
Week one: The preservation letter goes out. It demands that hospitals hold your pathology blocks and slides, that family members document their knowledge of your talc use in written statements, and that you photograph and preserve any product containers still in the home. This letter is the firewall against evidence disappearing.
Weeks two through four: We pull your complete medical record — pathology reports, imaging, surgical notes, treatment records, physician notes. We review your diagnosis, your cancer type, your stage, your treatment plan. We begin reconstructing your exposure history: what products, what frequency, what duration, what application method. We interview family members while their memories are available.
Months one through three: Expert review begins. For mesothelioma cases, a pathologist reviews your tissue blocks for asbestos and talc fibers. For ovarian cancer cases, a gynecologic oncologist or epidemiologist evaluates the causal connection. An exposure reconstruction expert builds the timeline. If your case has the facts to support it, we begin building the damages model — past and future medical costs, lost wages, lost earning capacity, pain and suffering, loss of consortium, and where the evidence supports it, punitive damages.
Months three through twelve: If your case is in the MDL, it is part of the consolidated pretrial proceeding. Discovery — the exchange of documents and testimony — is largely handled at the MDL level, which means the internal J&J documents, the expert depositions, and the scientific evidence are available. Your individual case is prepared for its own track — either a bellwether selection, a remand to your home district for trial, or a settlement negotiation.
Resolution: Cases resolve through settlement or trial. The MDL structure means that as bellwether verdicts accumulate — both plaintiff and defense — the settlement value of the remaining cases shifts. A strong plaintiff verdict pushes settlement values up. A defense verdict pushes them down. Your case’s specific strength determines where it falls in that range.
The Clock: Statutes of Limitation and the Discovery Rule
This is the section that may matter more than any other on this page, because the clock is the one thing that cannot be undone.
Every state has a statute of limitations — a deadline for filing a lawsuit. For personal injury and product liability claims, that deadline is typically between two and four years, depending on the state. For wrongful death claims, the deadline is often shorter — sometimes as little as one or two years from the date of death.
But talc cases present a unique problem: the injury — cancer — may not appear for decades after the exposure. A woman who used baby powder from 1980 to 2005 may not be diagnosed with ovarian cancer until 2020. A man who used body powder in the 1970s may not be diagnosed with mesothelioma until 2025. If the statute of limitations ran from the date of exposure, the deadline would have passed before the injury even existed.
This is why most states apply the discovery rule to latent disease cases:
“In actions involving latent injury or disease, the cause of action does not accrue until the plaintiff has discovered, or by reasonable diligence should have discovered, the injury and its cause.”
Under this rule — which is the prevailing doctrine across the majority of states — the clock does not start when you used the talc. It starts when you knew, or reasonably should have known, that you had cancer AND that your cancer was connected to talc use. For many plaintiffs, that connection was not apparent until news reports, scientific studies, or lawyer advertising brought the talc-cancer link to public attention in recent years.
However — and this is critical — the discovery rule is not unlimited. Some states impose a statute of repose — an outer deadline that can cut off a claim even if you have not yet discovered the injury. The rules vary by state. Some states start the clock from the date of diagnosis. Others from the date you should have connected the cancer to talc. Some have different rules for mesothelioma than for ovarian cancer. Some toll (pause) the clock for minors or for people who were incapacitated.
What this means for you: you cannot determine your deadline from a website. The statute of limitations that applies to your case depends on your state, your date of diagnosis, your date of discovery, and the specific rules your jurisdiction applies to latent disease claims. What we can tell you with certainty is this: the clock is shorter than people think, it is already running, and the only safe move is to have a lawyer evaluate it now — not next month, not after treatment ends, not after you “feel better.” Now.
Call us at 1-888-ATTY-911. The consultation is free. We will tell you honestly whether your deadline has passed or whether you still have time.
Your First Steps: What to Do and What Not to Do
If you or a loved one used talcum powder products and has been diagnosed with ovarian cancer, mesothelioma, or another cancer you believe may be related to talc exposure, here are the steps that matter — and the mistakes that destroy cases.
Do This
Document your talc usage history now. Write down every product you can remember using — Johnson’s Baby Powder, Shower to Shower, store brands. Write down the years you used them, how often, and how you applied them. Do this while your memory is fresh. Ask family members to do the same — their corroboration is evidence.
Preserve any physical evidence. If you still have old talc containers in your home — even empty ones — do not throw them away. Photograph them. Keep them in a sealed bag. The container itself can sometimes be tested for asbestos contamination, and the label identifies the specific product and potentially the lot.
Get your complete medical records. Request copies of your pathology reports, surgical notes, imaging, treatment records, and physician notes. If you have mesothelioma, ask whether your pathology tissue blocks are still being retained by the hospital — and if so, for how long. Tell us immediately so we can send a preservation letter.
Talk to a lawyer now. Not after treatment. Not after you “have time.” The statute of limitations is running, evidence is aging, and family members who can corroborate your usage history are not getting younger. The consultation is free and confidential.
Do Not Do This
Do not speak to anyone from Johnson & Johnson or any insurance company. If you receive a call, a letter, or a visit from anyone representing J&J or its insurers, do not answer questions, do not give a statement, and do not sign anything. Anything you say can and will be used to undermine your claim. The friendly voice on the phone is not your friend.
Do not post about your case on social media. Defense investigators monitor social media. A photograph of you at a family event can be used to argue you are not as injured as you claim. A post about your cancer diagnosis can be taken out of context. Silence is protection.
Do not assume it is too late. The discovery rule may protect you. But the only way to know is to have a lawyer evaluate your specific situation. The assumption that “too much time has passed” is the single most common reason people with valid claims never file them.
Do not assume the defense verdict means your case is worthless. One jury’s verdict in one case with one set of facts does not determine the value of your case. The strength of your exposure evidence, the type of cancer you have, the jurisdiction where your case would be filed, and the quality of your legal representation — these are the factors that decide your case, not a headline about someone else’s trial.
Frequently Asked Questions
Can I still sue Johnson & Johnson if they won this latest trial?
Yes. A defense verdict in one trial does not dismiss other cases. More than 68,000 talc cases remain in the federal MDL in New Jersey, and J&J’s three attempts to use bankruptcy to cap liability all failed. Each case is evaluated on its own facts. If you used talc products and were diagnosed with ovarian cancer or mesothelioma, your claim may still be viable — but the only way to know is to have a lawyer review your specific situation.
What does it mean that Johnson & Johnson “beat” a talc lawsuit?
It means that in that specific trial, with those specific plaintiffs, that specific jury was not persuaded that talc caused those women’s cancer. It does not mean the science is settled, it does not mean the MDL is closed, and it does not mean other plaintiffs cannot win. Mass tort bellwether trials produce mixed results by design — some plaintiffs win large verdicts, others lose. The Ingham verdict in Missouri — $4.69 billion, later reduced to approximately $2.12 billion and affirmed by the U.S. Supreme Court’s refusal to hear the appeal — shows that juries can and do find for plaintiffs in these cases.
How long do I have to file a talc cancer lawsuit?
The statute of limitations varies by state — typically between two and four years for personal injury claims, and sometimes shorter for wrongful death. However, most states apply the discovery rule to latent disease cases, meaning the clock may not start until you knew or should have known that your cancer was connected to talc use. Some states also have statutes of repose that impose an outer deadline regardless of discovery. You cannot determine your deadline from a website. Call us at 1-888-ATTY-911 for a free evaluation of your specific situation.
What types of cancer are linked to talcum powder?
Two types of cancer are at the center of the talc litigation. Ovarian cancer is linked to perineal (genital) use of talc-based body powder, based on the theory that talc particles travel to the ovaries and cause inflammation. Mesothelioma is linked to inhalation of asbestos-contaminated talc, based on the theory that some talc deposits contain naturally occurring asbestos fibers. The scientific link is more established for mesothelioma (because asbestos is a known Group 1 carcinogen) and more contested for ovarian cancer.
Did Johnson & Johnson know there was asbestos in their talc?
Internal corporate documents produced in litigation and reported in major news investigations show that J&J’s own testing detected asbestos in its talc on multiple occasions spanning decades — going back to the 1970s. The company’s internal communications discussed how to manage the regulatory and public-relations implications. In 2019, J&J voluntarily recalled a lot of Baby Powder after the FDA reported finding trace amounts of asbestos, though the company disputed the finding. J&J stopped selling talc-based Baby Powder in the U.S. and Canada in 2020.
What happened with Johnson & Johnson’s bankruptcy filings?
J&J attempted to use bankruptcy to cap its talc liability three times. It created entities (LTL Management LLC and Red River Talc LLC) to hold the liability and filed them for Chapter 11 bankruptcy, hoping a bankruptcy judge would impose a global settlement binding all claimants. All three attempts were dismissed — the most recent on March 31, 2025, by Judge Christopher Lopez of the U.S. Bankruptcy Court for the Southern District of Texas, who cited vote-solicitation irregularities and impermissible nonconsensual third-party releases. The cases are now proceeding in the civil tort system.
What is my talc cancer case worth?
No honest lawyer can answer that question without reviewing your medical records, exposure history, and the specific facts of your case. Verified verdict results in the talc MDL range from defense verdicts (zero recovery) to multi-billion-dollar awards. The Ingham case produced a verdict of $4.69 billion for 22 plaintiffs, later reduced to approximately $2.12 billion and affirmed. Individual case value depends on cancer type, exposure strength, jurisdiction, medical costs, lost earnings, and punitive damage exposure. Past results depend on the facts of each case and do not guarantee future outcomes.
Do I need a lawyer for a talc cancer claim?
You absolutely need a lawyer. Talc litigation is mass tort litigation — it involves complex scientific evidence, corporate document discovery, expert witnesses in epidemiology and pathology, and a federal MDL structure that a non-lawyer cannot effectively work through. Johnson & Johnson is represented by some of the most sophisticated defense firms in the country. A person who tries to handle a talc claim alone will be outmatched at every stage. The consultation is free, and we do not get paid unless we win your case.
What evidence do I need for a talc lawsuit?
The most important evidence is your usage history — what product, how often, how many years, and how it was applied. This is proven through your own testimony and family corroboration. Your medical records — pathology, diagnosis, treatment — are essential. For mesothelioma, tissue blocks can sometimes be analyzed for asbestos and talc fibers. Any physical product containers you still have are valuable. And the internal J&J documents showing corporate knowledge of asbestos in talc are available through the MDL’s discovery process. We help you gather and preserve all of this.
Has Johnson & Johnson settled any talc cases?
J&J has settled individual talc cases and groups of cases over the years, though specific settlement amounts are typically confidential. The company has also proposed global settlement frameworks at various points, some tied to its bankruptcy attempts. After the third bankruptcy dismissal in March 2025, reporting indicates J&J has pivoted to defending cases in the tort system. Settlements, when they occur, contain no admission of liability — the company always maintains its products are safe. The existence of settlements does not mean your case will settle, and the amount of any settlement depends entirely on the strength of your individual case.
Why Attorney911
Ralph Manginello has spent 27-plus years in courtrooms — including federal court — building cases against corporations that knew more than they told the people they were supposed to protect. He was a journalist before he was a lawyer, which means he knows how to find the document the company hoped no one would read. He is admitted to the U.S. District Court for the Southern District of Texas and has spent his career in the trial trenches. Ralph’s background and approach is the foundation of how we build these cases — document by document, fact by fact, until the picture is complete.
Lupe Peña spent years inside a national insurance-defense firm before he joined our side of the table. He sat in the rooms where adjusters and their valuation software decided how to deny, delay, and devalue claims — the rooms where the defense playbook is written. He knows how the other side prices a claim, what evidence they fear, and what moves they will make before they make them. He brings that insider knowledge to every case we handle. Lupe’s experience and perspective is the advantage we use for our clients — and he conducts full consultations in Spanish, without an interpreter, for families who need it.
Our firm has recovered more than $50 million for injured clients. We handle cases on contingency — 33.33% before trial, 40% if the case goes to trial. We do not get paid unless we win your case. The consultation is free, and we have 24/7 live staff — not an answering service. Call 1-888-ATTY-911 and a real person will answer.
We are not the firm that tells you what you want to hear. We are the firm that tells you the truth — about your case, about the science, about the timeline, about the defense you will face — and then builds the strongest possible claim around that truth. If your case is strong, we will tell you and we will fight. If your case is weak, we will tell you that too, because honesty is the only foundation that holds when the fight gets hard.
Hablamos Español.
The headline you read said Johnson & Johnson won. The truth is that the fight is not over — not for 68,000 claimants, and not for you. Call us. The consultation is free. The clock is running. And the evidence you need is aging every day you wait.
1-888-ATTY-911. 24 hours a day. A real person answers.